Hepatitis C virus and its inhibitors the polymerase as a target for nucleoside and nucleotide analogs

Cancer-Causing Viruses and their Inhibitors

Volumn , Issue , 2014, Pages 41-84

  Deval, Jerome ^a   Huber, Martin ^b  

^a Alios BioPharma Inc   (United States)

^b Humapharm   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944384578     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16780     Document Type: Chapter

References (157)

1. Adachi T, Ago H, Habuka N, et al. (2002). The essential role of C-terminal residues in regulating the activity of hepatitis C virus RNA-dependent RNA polymerase. Biochim Biophys Acta 1601: 38-48.
2. Ago H, Adachi T, Yoshida A, et al. (1999). Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7: 1417-26.
3. Ali S, Leveque V, Le Pogam S, et al. (2008). Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 52(12): 4356-69.
4. Alter HJ, Seeff LB. (2000). Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis 20: 17-35.
5. Berke JM, Vijgen L, Lachau-Durand S, et al. (2011). Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 55: 3812-20.
6. Bichko V, Tausek M, Qu L, et al. (2005). Enhanced antiviral activity of NM107, alone or in combination with interferon a. J Hepatol 42: S154.
7. Boonstra A, van der Laan LJ, Vanwolleghem T, et al. (2009). Experimental models for hepatitis C viral infection. Hepatology 50: 1646-55.
8. Bressanelli S, Tomei L, Rey FA, et al. (2002). Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol 76: 3482-92.
9. Bressanelli S, Tomei L, Roussel A, et al. (1999). Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 96: 13034-9.
10. Bristol-Myers Squibb Company. (2012). Bristol-Myers Squibb discontinues development of BMS-986094, an investigational NS5B nucleotide for the treatment of Hepatitis C (Press release of August 23. Internet) Available from: http://news.bms.com/press-release/financial-news/bristol-myers-squibb-discontinues-development-bms-986094-investigationa (accessed June 14, 2013).
11. Buckwold VE, Beer BE, Donis RO. (2003). Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. Antiviral Res 60: 1-15.
12. Bukh J. (2004). A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39: 1469-75.
13. Caillet-Saguy C, Simister PC, Bressanelli S. (2011). An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors. J Mol Biol 414: 370-84.
14. Carroll SS, Koeplinger K, Vavrek M, et al. (2011). Antiviral efficacy upon administration of a HepDirect prodrug of 2′-C-methylcytidine to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 55: 3854-60.
15. Carroll SS, LaFemina R, Hall DL, et al. (2002). Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. Patent publication no. WO/2002/057425.
16. Carroll SS, Ludmerer S, Handt L, et al. (2009). Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 53: 926-34.
17. Carroll SS, Tomassini JE, Bosserman M, et al. (2003). Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem 278: 11979-84.
18. Chang W, Bao D, Chun BK, et al. (2011). Discovery of PSI-353661, a novel purine nucleotide prodrug for the treatment of HCV infection. ACS Med Chem Lett 2: 130-5.
19. Chen CM, He Y, Lu L, et al. (2007). Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother 51: 4290-6.
20. Choo QL, Kuo G, Weiner AJ, et al. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-62.
21. Clark JL, Mason JC, Hollecker L, et al. (2006). Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorg Med Chem Lett 16: 1712-15.
22. Coelmont L, Paeshuyse J, Windisch MP, et al. (2006). Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 50: 3444-6.
23. Cretton-Scott E, Perigaud C, Peyrottes S, et al. (2008). In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J Hepatol 48: S220.
24. De Clercq E. (2012). The race for interferon-free HCV therapies: A snapshot by the spring of 2012. Rev Med Virol 22: 392-411.
25. Deval J, Powdrill MH, D’Abramo CM, et al. (2007). Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 51: 2920-8.
26. Di Marco S, Volpari C, Tomei L, et al. (2005). Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 280: 29765-70.
27. Ding Y, Girardet JL, Hong Z, et al. (2005). Synthesis of 9-(2-beta-C-methyl-beta-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCVRNA replication. Bioorg Med Chem Lett 15(3): 709-13.
28. Dorner M, Horwitz JA, Robbins JB, et al. (2011). A genetically humanized mouse model for hepatitis C virus infection. Nature 474: 208-11.
29. Dutartre H, Bussetta C, Boretto J, et al. (2006). General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues. Antimicrob Agents Chemother 50: 4161-9.
30. Eldrup AB, Allerson CR, Bennett CF, et al. (2004a). Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem 47: 2283-95.
31. Eldrup AB, Prhavc M, Brooks J, et al. (2004b). Structure-activity relationship of heterobase-modified 2′-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J Med Chem 47: 5284-97.
32. Erion MD, Reddy KR, Boyer SH, et al. (2004). Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J Am Chem Soc 126: 5154-63.
33. Ferrari E, He Z, Palermo RE, et al. (2008). Hepatitis C virus NS5B polymerase exhibits distinct nucleotide requirements for initiation and elongation. J Biol Chem 283: 33893-901.
34. Fogt J, Januszczyk P, Framski G, et al. (2008). Synthesis and antiviral activity of novel derivatives of 2′-beta-C-methylcytidine. Nucleic Acids Symp Ser (Oxf) 52: 605-6.
35. Furman PA, Lam AM, Murakami E. (2009). Nucleoside analog inhibitors of hepatitis C viral replication: Recent advances, challenges and trends. Future Med Chem 1: 1429-52.
36. Furman PA, Murakami E, Niu C, et al. (2011). Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res 91: 120-32.
37. Gane EJ, Rodriguez-Torres M, Nelson DR, et al. (2010). Sustained virologic response (SVR) following RG7128 1500mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. J Hepatol 52: S16.
38. Gane EJ, Stedman CA, Hyland RH, et al. (2013). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34-44.
39. Golitsina NL, Danehy FT, Jr, Fellows R, et al. (2010). Evaluation of the role of three candidate human kinases in the conversion of the hepatitis C virus inhibitor 2′-C-methyl-cytidine to its 5′-monophosphate metabolite. Antiviral Res 85: 470-81.
40. Gouklani H, Bull RA, Beyer C, et al. (2012). Hepatitis C virus nonstructural protein 5B is involved in virus morphogenesis. J Virol 86: 5080-8.
41. Gunic E, Girardet JL, Ramasamy K, et al. (2007). Cyclic monophosphate prodrugs of base-modified 2′-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg Med Chem Lett 17: 2452-55.
42. Hang JQ, Yang Y, Harris SF, et al. (2009). Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J Biol Chem 284: 15517-29.
43. Harrus D, Ahmed-El-Sayed N, Simister PC, et al. (2010). Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis. J Biol Chem 285: 32906-18.
44. Herbst DA, Jr, Reddy KR. (2013). Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 22: 527-36.
45. Hernandez-Santiago BI, Beltran T, Stuyver L, et al. (2004). Metabolism of the anti-hepatitis C virus nucleoside beta-d-N4-hydroxycytidine in different liver cells. Antimicrob Agents Chemother 48: 4636-42.
46. Hong Z, Cameron CE, Walker MP, et al. (2001). A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 285: 6-11.
47. Idenix Pharmaceuticals. (2013). Idenix Pharmaceuticals provides update on IDX184 and IDX19368 development programs (Press release of February 4, 2013. Internet) Available from: http://ir.idenix.com/releasedetail.cfm?ReleaseID=737733 (Accessed June 14, 2013).
48. Ilan E, Arazi J, Nussbaum O, et al. (2002). The hepatitis C virus (HCV)-trimera mouse: A model for evaluation of agents against HCV. J Infect Dis 185: 153-61.
49. Jensen DM. (2011). A new era of hepatitis C therapy begins. N Engl J Med 364: 1272-4.
50. Jin Z, Leveque V, Ma H, et al. (2012). Assembly, purification, and pre-steady-state kinetic analysis of active RNA-dependent RNA polymerase elongation complex. J Biol Chem 287: 10674-83.
51. Klumpp K, Kalayanov G, Ma H, et al. (2008). 2′-deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J Biol Chem 283: 2167-75.
52. Klumpp K, Leveque V, Le Pogam S, et al. (2006). The novel nucleoside analog r1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 281: 3793-9.
53. Koh YH, Shim JH, Wu JZ, et al. (2005). Design, synthesis, and antiviral activity of adenosine 5′-phosphonate analogues as chain terminators against hepatitis C virus. J Med Chem 48: 2867-75.
54. Kowdley KV, Lawitz E, Crespo I, et al. (2013). Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (atomic): An open-label, randomised, multicentre phase 2 trial. Lancet 381: 2100-7.
55. Lalezari J, Asmuth D, Casiro A, et al. (2012). Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 56: 6372-8.
56. Lalezari J, Poordad F, Mehra P, et al. (2010). Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (pegifn) and ribavirin (rbv) in treatment-naive HCV genotype 1-infected subjects. J Hepatol 52: S469.
57. Lam AM, Espiritu C, Bansal S, et al. (2011a). Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol 85(23): 12334-42.
58. Lam AM, Espiritu C, Murakami E, et al. (2011b). Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methylguanosine. Antimicrob Agents Chemother 55: 2566-75.
59. Lam AM, Murakami E, Espiritu C, et al. (2010). Psi-7851, a pronucleotide of {beta}-d-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 54: 3187-96.
60. Lawitz E, Lalezari JP, Hassanein T, et al. (2011a). Once-daily PSI-7977 plus Peg/RBV in treatment naïve patients with HCV GT1: Robust end of treatment response rates are sustained post treatment. Hepatology 54: 472A.
61. Lawitz E, Lalezari JP, Hassanein T, et al. (2013a). Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial. Lancet Infect Dis 13: 401-8.
62. Lawitz E, Lalezari JP, Freilich B, et al. (2012a). BMS-986094 (INX-08189) plus peginterferon alfa-2a and ribavirin results in increased rates of rapid virologic response (RVR) and eRVR in treatment-naïve HCV-genotype 2/3 patients compared to peginterferon alfa-2a and ribavirin: Week 12 results. Hepatology 56: 566A.
63. Lawitz E, Box TD, Pruitt R, et al. (2012b). High rates of rapid virologic response (RVR) and complete early virologic response (cEVR) with IDX184, pegylated interferon and ribavirin in genotype 1 HCV infected subjects: Interim results. Hepatology 56: 1006A.
64. Lawitz E, Lalezari JP, Rodriguez-Torres M, et al. (2010). High rapid virologic response (RVR) with PSI-7977 QD plus PEG-IFN/RBV in a 28-day phase 2A trial. Hepatology 52: 706A.
65. Lawitz E, Rodriguez-Torres M, Denning J, et al. (2011b). Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCVRNA< lod at day 14: First purine/pyrimidine clinical combination data (the nuclear study). J Hepatol 54: S543.
66. Lawitz E, Rodriguez-Torres M, Denning JM, et al. (2013b). Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Antimicrob Agents Chemother 57: 1209-17.
67. Le Pogam S, Jiang WR, Leveque V, et al. (2006). In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351: 349-59.
68. Lesburg CA, Cable MB, Ferrari E, et al. (1999). Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6: 937-43.
69. Leveque VJ, Wang QM. (2002). RNA-dependent RNA polymerase encoded by hepatitis C virus: Biomedical applications. Cell Mol Life Sci 59: 909-19.
70. Li F, Maag H, Alfredson T. (2008). Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 97: 1109-34.
71. Lindenbach BD, Evans MJ, Syder AJ, et al. (2005). Complete replication of hepatitis C virus in cell culture. Science 309: 623-6.
72. Lindenbach BD, Meuleman P, Ploss A, et al. (2006). Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 103: 3805-9.
73. Lohmann V, Korner F, Herian U, et al. (1997). Biochemical properties of hepatitis C virus NS5BRNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 71: 8416-28.
74. Lohmann V, Korner F, Koch J, et al. (1999a). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-13.
75. Lohmann V, Overton H, Bartenschlager R. (1999b). Selective stimulation of hepatitis C virus and pestivirus NS5BRNA polymerase activity by GTP. J Biol Chem 274: 10807-15.
76. Lohmann V, Roos A, Korner F, et al. (1998). Biochemical and kinetic analyses of NS5BRNA-dependent RNA polymerase of the hepatitis C virus. Virology 249: 108-18.
77. Love RA, Parge HE, Yu X, et al. (2003). Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5BRNA polymerase enzyme. J Virol 77: 7575-81.
78. Luo G, Hamatake RK, Mathis DM, et al. (2000). De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J Virol 74: 851-63.
79. Ma H, Jiang WR, Robledo N, et al. (2007). Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 282: 29812-20.
80. Ma H, Leveque V, De Witte A, et al. (2005). Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors. Virology 332: 8-15.
81. Maag D, Castro C, Hong Z, et al. (2001). Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 276: 46094-8.
82. Maag H, Rydzewski RM, McRoberts MJ, et al. (1992). Synthesis and anti-HIV activity of 4′-azido- and 4′-methoxynucleosides. J Med Chem 35: 1440-51.
83. McCarville JF, Dubuc G, Donovan E, et al. (2011). No resistance to IDX184 was detected in 3-day and 14-day clinical studies of IDX184 in genotype 1 infected HCV subjects. J Hepatol 54: S488-9.
84. Madela K, McGuigan C. (2012). Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs. Future Med Chem 4: 625-650.
85. McCown MF, Rajyaguru S, Le Pogam S, et al. (2008). The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 52: 1604-12.
86. McGuigan C, Gilles A, Madela K, et al. (2010a). Phosphoramidate protides of 2′-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties. J Med Chem 53: 4949-57.
87. McGuigan C, Kelleher MR, Perrone P, et al. (2009). The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4′-azidocytidine (R1479). Bioorg Med Chem Lett 19: 4250-4.
88. McGuigan C, Madela K, Aljarah M, et al. (2010b). Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg Med Chem Lett 20: 4850-4.
89. McGuigan C, Madela K, Aljarah M, et al. (2011a). Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: Application to anti-HCV agents. J Med Chem 54: 8632-45.
90. McGuigan C, Madela K, Aljarah M, et al. (2011b). Dual pro-drugs of 2′-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus. Bioorg Med Chem Lett 21: 6007-12.
91. Mehellou Y, Balzarini J, McGuigan C. (2009). Aryloxy phosphoramidate triesters: A technology for delivering monophosphorylated nucleosides and sugars into cells. Chem Med Chem 4: 1779-91.
92. Mercer DF. (2011). Animal models for studying hepatitis C and alcohol effects on liver. World J Gastroenterol 17: 2515-19.
93. Migliaccio G, Tomassini JE, Carroll SS, et al. (2003). Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278: 49164-70.
94. Moradpour D, Penin F, Rice CM. (2007). Replication of hepatitis C virus. Nat Rev Microbiol 5: 453-63.
95. Mosley RT, Edwards TE, Murakami E, et al. (2012). Structure of hepatitis C virus polymerase in complex with primer-template RNA. J Virol 86: 6503-11.
96. Murakami E, Niu C, Bao H, et al. (2008). The mechanism of action of beta-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-d-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 52: 458-64.
97. Nelson DR, Zeuzem S, Andreone P, et al. (2012). Balapiravir plus peginterferon alfa-2a (40kd)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol 11: 15-31.
98. Nilsson M, Kalayanov G, Winqvist A, et al. (2012). Discovery of 4′-azido-2′-deoxy-2′-C-methyl cytidine and prodrugs thereof: A potent inhibitor of hepatitis C virus replication. Bioorg Med Chem Lett 22: 3265-8.
99. Nyanguile O, Devogelaere B, Vijgen L, et al. (2010). 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus. J Virol 84: 2923-34.
100. Ohara E, Hiraga N, Imamura M, et al. (2011). Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol 54: 872-8.
101. Olsen DB, Eldrup AB, Bartholomew L, et al. (2004). A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 48: 3944-53.
102. Palmer M. (2013). The future of hepatitis C beyond protease inhibitors-will hepatitis C be a disease of the past? PractHepatol 36: 13-22.
103. Pawlotsky JM, Chevaliez S, McHutchison JG. (2007). The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132: 1979-98.
104. Pawlotsky JM, Najera I, Jacobson I. (2012). Resistance to mericitabine, a nucleoside analogue inhibitor of HCVRNA-dependent RNA polymerase. Antivir Ther 17: 411-23.
105. Perrone P, Daverio F, Valente R, et al. (2007a). First example of phosphoramidate approach applied to a 4′-substituted purine nucleoside (4′-azidoadenosine): Conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus. J Med Chem 50: 5463-70.
106. Perrone P, Luoni GM, Kelleher MR, et al. (2007b). Application of the phosphoramidate protide approach to 4′-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J Med Chem 50: 1840-9.
107. Peyrottes S, Egron D, Lefebvre I, et al. (2004). Sate pronucleotide approaches: An overview. Mini Rev Med Chem 4: 395-408.
108. Pierra C, Amador A, Benzaria S, et al. (2006). Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 49: 6614-20.
109. Pockros PJ. (2012). Interferon-free hepatitis C therapy: How close are we? Drugs 72: 1825-31.
110. Pockros PJ, Jensen D, Tsai N, et al. (2013). JUMP-C: A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 58: 514-23.
111. Pockros PJ, Nelson D, Godofsky E, et al. (2008). R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48: 385-97.
112. Poordad F, Chee GM. (2012). Interferon free hepatitis C treatment regimens: The beginning of another era. Curr Gastroenterol Rep 14: 74-7.
113. Poordad F, Lawitz EJ, Gitlin N, et al. (2007). Efficacy and safety of valopicitabine in combination with pegylated interferon-alpha (pegifn) and ribavirin (RBV) in patients with chronic hepatitis C. Hepatology 46: 866A.
114. Powdrill MH, Tchesnokov EP, Kozak RA, et al. (2011). Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A 108: 20509-13.
115. Qin W, Luo H, Nomura T, et al. (2002). Oligomeric interaction of hepatitis C virus NS5B is critical for catalytic activity of RNA-dependent RNA polymerase. J Biol Chem 277: 2132-7.
116. Quezada EM, Kane CM. (2013). The stimulatory mechanism of hepatitis C virus NS5A protein on the NS5B catalyzed replication reaction in vitro. Open Biochem J 7: 11-14.
117. Ranjith-Kumar CT, Gutshall L, Sarisky RT, et al. (2003). Multiple interactions within the hepatitis C virus RNA polymerase repress primer-dependent RNA synthesis. J Mol Biol 330: 675-85.
118. Reddy KR, Rodriguez-Torres M, Gane EJ, et al. (2007). Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCVRNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 46: 862A-3.
119. Reddy PG, Chun BK, Zhang HR, et al. (2011). Stereoselective synthesis of PSI-352938: A beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyl-3′,5′-cyclic phosphate nucleotide prodrug for the treatment of HCV. J Org Chem 76: 3782-90.
120. Roberts SK, Cooksley G, Dore GJ, et al. (2008). Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 48: 398-406.
121. Rodriguez-Torres M, Lawitz E, Hazan L, et al. (2011). Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7 days of oral therapy in naïvegenotype-1 chronic HCV patients. Hepatology 54: 535A.
122. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. (2013). Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol 58: 663-8.
123. Rondla R, Coats SJ, McBrayer TR, et al. (2009). Anti-hepatitis C virus activity of novel beta-d-2′-C-methyl-4′-azido pyrimidine nucleoside phosphoramidate prodrugs. Antivir Chem Chemother 20: 99-106.
124. Scrima N, Caillet-Saguy C, Ventura M, et al. (2012). Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405. J Virol 86: 7107-17.
125. Shi ST, Herlihy KJ, Graham JP, et al. (2009). Preclinical characterization of pf-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 53: 2544-52.
126. Shimakami T, Hijikata M, Luo H, et al. (2004). Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol 78(6): 2738-48.
127. Shirota Y, Luo H, Qin W, et al. (2002). Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 277: 11149-55.
128. Smith DB, Kalayanov G, Sund C, et al. (2009a). The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4′-azidocytidine against hepatitis C virus replication: The discovery of 4′-azido-2′-deoxy-2′-fluorocytidine and 4′-azido-2′-dideoxy-2′,2′-difluorocytidine. J Med Chem 52: 2971-8.
129. Smith DB, Kalayanov G, Sund C, et al. (2009b). The design, synthesis, and antiviral activity of 4′-azidocytidine analogues against hepatitis C virus replication: The discovery of 4′-azidoarabinocytidine. J Med Chem 52: 219-23.
130. Smith DB, Martin JA, Klumpp K, et al. (2007). Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication: The discovery of R1479. Bioorg Med Chem Lett 17: 2570-6.
131. Smith KL, Lai VC, Prigaro BJ, et al. (2004). Synthesis of new 2′-beta-C-methyl related triciribine analogues as anti-HCV agents. Bioorg Med Chem Lett 14: 3517-20.
132. Sofia MJ, Bao D, Chang W, et al. (2010). Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53: 7202-18.
133. Sommadossi JP, La Colla P. (2001a). Methods and compositions for treating flaviviruses and pestiviruses. Patent publication no. WO/2001/092282.
134. Sommadossi JP, La Colla P. (2001b). Methods and compositions for treating hepatitis C virus. Patent publication no. WO/2001/090121.
135. Sorbera LA, Castaner J, Leeson PA. (2006). Valopicitabine. Drugs Fut 31: 320-4.
136. Standring DN, Lanford R, Wright T, et al. (2003). NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee. J Hepatology 38: 3.
137. Stuyver LJ, McBrayer TR, Tharnish PM, et al. (2006). Inhibition of hepatitis C replicon RNA synthesis by beta-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine: A specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 17: 79-87.
138. Stuyver LJ, McBrayer TR, Whitaker T, et al. (2004). Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2′-deoxy-2′-fluorocytidine. Antimicrob Agents Chemother 48: 651-4.
139. Stuyver LJ, Whitaker T, McBrayer TR, et al. (2003). Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 47: 244-54.
140. Svarovskaia ES, Dvory-Sobol H, Gontcharova V, et al. (2012). Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7977)-containing regimens in phase 2 studies. AASLD abstract 753. Hepatology 56: 551A.
141. Tomassini JE, Boots E, Gan L, et al. (2003). An in vitro flaviviridae replicase system capable of authentic RNA replication. Virology 313: 274-85.
142. Tomassini JE, Getty K, Stahlhut MW, et al. (2005). Inhibitory effect of 2′-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells. Antimicrob Agents Chemother 49: 2050-8.
143. Tomei L, Altamura S, Bartholomew L, et al. (2003). Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 77: 13225-31.
144. Tomei L, Vitale RL, Incitti I, et al. (2000). Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J Gen Virol 81: 759-67.
145. Toniutto P, Fabris C, Bitetto D, et al. (2007). Valopicitabine dihydrochloride: A specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs 8: 150-8.
146. Valiaeva N, Wyles DL, Schooley RT, et al. (2011). Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. Bioorg Med Chem 19: 4616-25.
147. Vernachio JH, Bleiman B, Bryant KD, et al. (2011). INX-08189, a phosphoramidate prodrug of 6-o-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 55: 1843-51.
148. Vo NV, Tuler JR, Lai MM. (2004). Enzymatic characterization of the full-length and C-terminally truncated hepatitis C virus RNA polymerases: Function of the last 21 amino acids of the C terminus in template binding and RNA synthesis. Biochemistry 43: 10579-91.
149. Wakita T, Pietschmann T, Kato T, et al. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-6.
150. Wang QM, Hockman MA, Staschke K, et al. (2002). Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J Virol 76: 3865-72.
151. Wedemeyer H, Jensen D, Herring R, Jr, et al. (2013). PROPEL: A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology 58: 524-37.
152. Wyles DL, Kaihara KA, Korba BE, et al. (2009). The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1a, 1b, and 2a replicons. Antimicrob Agents Chemother 53: 2660-2.
153. Yamashita T, Kaneko S, Shirota Y, et al. (1998). RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J Biol Chem 273: 15479-86.
154. Zamyatkin DF, Parra F, Alonso JM, et al. (2008). Structural insights into mechanisms of catalysis and inhibition in Norwalk virus polymerase. J Biol Chem 283: 7705-12.
155. Zeuzem S, Andreone P, Pol S, et al. (2011). Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417-28.
156. Zhong J, Gastaminza P, Chung J, et al. (2006). Persistent hepatitis C virus infection in vitro: Coevolution of virus and host. J Virol 80: 11082-93.
157. Zhou XJ, Pietropaolo K, Chen J, et al. (2011). Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob Agents Chemother 55: 76-81.